MindMaze Therapeutics secures 8.0 million CHF for US expansion

MindMaze Therapeutics is undergoing a significant financial restructuring to support its clinical pipeline and expansion into the United States. The company has secured a definitive agreement for an 8.0 million CHF equity financing round through Neuro. io Group SA. An initial tranche of 4.0 million CHF has already been received, with the remaining funds scheduled to be disbursed in two installments during September and November.

The company faces substantial market pressure, with its share price dropping 6.7% to 0.1680 CHF on Friday, continuing a year-to-date decline of approximately 84%. Financial reports for the first half of the year indicate a revenue of only 0.5 million CHF against a net loss of 6.9 million CHF.

Under the leadership of CEO Zach Henderson, MindMaze is focusing on commercial scaling. A key component of this strategy is a partnership with Vibra Healthcare intended to expand the company's commercial capabilities within the US market.